CRDL
Income statement / Annual
Last year (2023), Cardiol Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Cardiol Therapeutics Inc.'s net income was -$28.13 M.
See Cardiol Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00
|
$0.00
|
$78,760.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$248,355.00 |
$219,908.00 |
$0.00 |
$229,539.00 |
$150,572.00 |
$91,492.00 |
$53,341.00 |
| Gross Profit |
-$248,355.00 |
-$219,908.00 |
$78,760.00 |
-$229,539.00 |
-$150,572.00 |
-$91,492.00 |
-$53,341.00 |
| Gross Profit Ratio |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$14.22 M
|
$18.96 M
|
$10.87 M
|
$10.52 M
|
$3.53 M
|
$1.53 M
|
$441,257.00
|
| General & Administrative
Expenses |
$15.56 M
|
$22.37 M
|
$27.87 M
|
$9.95 M
|
$10.45 M
|
$5.87 M
|
$1.10 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$15.56 M
|
$22.37 M
|
$27.87 M
|
$9.95 M
|
$10.45 M
|
$5.87 M
|
$1.10 M
|
| Other Expenses |
$0.00 |
$164,443.00 |
$112,229.00 |
$7,398.00 |
$298,795.00 |
$0.00 |
-$60,562.00 |
| Operating Expenses |
$29.79 M |
$41.34 M |
$38.74 M |
$20.69 M |
$14.13 M |
$7.49 M |
$1.60 M |
| Cost And Expenses |
$29.79 M |
$41.34 M |
$38.74 M |
$20.69 M |
$14.13 M |
$7.49 M |
$1.60 M |
| Interest Income |
$2,038.47 |
$1.24 M |
$106,001.00 |
$76,583.00 |
$245,422.00 |
$103,306.00 |
$6,118.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$621.00 |
$663,373.00 |
$60,562.00 |
| Depreciation &
Amortization |
$195,264.00
|
$219,908.00
|
$220,421.00
|
$229,539.00
|
$150,572.00
|
$91,492.00
|
$53,341.00
|
| EBITDA |
-$29.59 M
|
-$41.16 M
|
-$38.44 M
|
-$20.46 M
|
-$11.77 M
|
-$7.30 M
|
-$1.50 M
|
| EBITDA Ratio |
0 |
0 |
-574.56 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
-577.36
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$1.66 M
|
$10.41 M
|
$7.03 M
|
-$34,455.00
|
-$1.94 M
|
-$8.50 M
|
-$71,614.00
|
| Income Before Tax |
-$28.13 M |
-$30.93 M |
-$31.64 M |
-$20.64 M |
-$13.68 M |
-$15.89 M |
-$1.66 M |
| Income Before Tax Ratio
|
0
|
0
|
-401.7
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$10.24 M |
-$6.91 M |
$7,398.00 |
$299,416.00 |
$663,373.00 |
$60,562.00 |
| Net Income |
-$28.13 M |
-$30.93 M |
-$31.64 M |
-$20.64 M |
-$13.68 M |
-$15.89 M |
-$1.66 M |
| Net Income Ratio |
0 |
0 |
-401.7 |
0 |
0 |
0 |
0 |
| EPS |
-0.44 |
-0.49 |
-0.73 |
-0.69 |
-0.53 |
-1.03 |
-0.0731 |
| EPS Diluted |
-0.44 |
-0.49 |
-0.73 |
-0.69 |
-0.53 |
-1.03 |
-0.0731 |
| Weighted Average Shares
Out |
$64.46 M
|
$62.51 M
|
$43.22 M
|
$29.86 M
|
$25.82 M
|
$15.37 M
|
$22.71 M
|
| Weighted Average Shares
Out Diluted |
$64.46 M
|
$62.51 M
|
$43.22 M
|
$29.86 M
|
$25.82 M
|
$15.37 M
|
$22.71 M
|
| Link |
|
|
|
|
|
|
|
